骨髓间充质干细胞在大鼠体内的迁移研究

目的:将体外预先标记的骨髓间充质干细胞(mesenchymalstemcells,MSCs)移植到大鼠脑内观察细胞的存活和转归,从在体(invivo)角度阐明MSCs在中枢神经系统疾病细胞治疗中的潜在应用前景。首先用DiI在体外标记MSCs。将标记后的MSCs分别移植到大鼠纹状体和侧脑室,在移植后2w和4w灌杀动物,进行脑组织及脊髓的冰冻切片,在荧光显微镜下观察细胞的存活与转归。结果:移植到纹状体的MSCs可沿针道向周围实质迁移,迁移的最远距离可达0.2mm。并且,在大脑皮层及其他脑实质的血管壁、血管中以及血管周围还可见到标记细胞;而移植到侧脑室的MSCs则主要沿脑室系统迁移,细胞主要分布在移植侧侧脑室,对侧脑室与第四脑室也有分布,也有少量细胞沿侧脑室向周围实质迁移,迁移的最远距离为0.23mm。还可见到沿胼胝体向对侧脑室迁移的细胞流,甚至有个别细胞迁移至脊髓腰段。所有动物在细胞移植后4周均未发现肿瘤形成。结论:MSCs脑内移植后可以在中枢神经系统内存活并迁移,无致瘤性。结果提示骨髓间充质细胞是很多疾病细胞与基因治疗的有力工具。     

骨髓间充质干细胞源神经细胞移植治疗帕金森病大鼠模型

目的探讨骨髓间充质干细胞（mesenchymal stemcells,MSCs）源神经细胞脑内移植对帕金森病（Parkinson s disease,PD）大鼠的治疗作用。方法贴壁培养法分离、培养大鼠骨髓MSCs,脑匀浆上清诱导第3代MSCs向神经细胞分化,采用免疫细胞化学法鉴定诱导分化后细胞的性质,激光共聚焦显微镜检测诱导前后细胞Ca2＋浓度变化,6只PD大鼠行纹状体内MSCs源神经细胞移植作为细胞移植组,6只PD大鼠作为对照组。细胞移植术后4周检测PD大鼠的行为变化,观察移植细胞在脑内的分布情况。结果倒置显微镜下可见MSCs呈纺锤形和多角形,有1～2个核仁,MSCs经脑匀浆上清诱导后其胞体折光性增强,发出数个细长突起,互相交织成网,有的似轴突。诱导后细胞表达神经元特异性标志物神经元特异性烯醇化酶（NSE）和神经丝蛋白（NF）,胞质Ca2＋荧光强度显著增强,可推测诱导后的细胞为MSCs源神经细胞,将BrdU标记的MSCs源神经细胞移植到PD大鼠纹状体治疗4周后,可见细胞散在分布于注射侧脑组织,有少量细胞可迁移到对侧脑组织,PD大鼠的旋转行为得到显著改善。结论MSCs源神经细胞移植治疗帕金森病大鼠可使其旋转行为得到改善。     

BDNF基因工程细胞对帕金森大鼠纹状体多巴胺及其代谢物影响的研究

目的:观察经侧脑室移植pIRESneo-EGFP-BDNF修饰骨髓间充质干细胞(MSCs)对帕金森病(PD)大鼠纹状体多巴胺(DA)及代谢产物的影响。方法:采用电穿孔法将pIRESneo-EGFP-BDNF转染至骨髓MSCs;制备PD大鼠模型,随机分为Sham组,PD组,MSCs组,脑源性神经生长因子(BDNF)组,经侧脑室移植MSCs或pIRESneo-EGFP-BDNF修饰骨髓MSCs,术后2周,4周,8周,腹腔注射阿朴吗啡(APO)诱导PD大鼠旋转行为;应用高效液相色谱测定各组大鼠纹状体内多巴胺(DA)、高香草酸(HVA)及二羟苯乙酸(DOPAC)。结果:移植术后2周,4周,8周BDNF组、MSCs组大鼠与PD组比较旋转次数明显减少(P<0.05),以BDNF组改善更为明显。移植细胞干预PD模型8周后BDNF组、MSCs组大鼠纹状体DA、HVA、DOPAC较PD组明显提高(P<0.01),以BDNF组更为显著。结论:经侧脑室移植pIRESneo-EGFP-BDNF修饰的骨髓MSCs干预PD大鼠模型,显著降低PD大鼠纹状体内DA代谢率,提高DA水平,改善PD大鼠的行为能力。     

骨髓间充质干细胞黑质内移植对帕金森病大鼠的治疗作用

目的探索骨髓间充质干细胞（BMSCs）移植到帕金森病（Parkinson’s disease,PD）大鼠毁损侧黑质内,PD模型大鼠的姿势不对称性和黑质及纹状体内酪氨酸羟化酶（tyrosinehy droxylase,TH）表达的改变,以及BM—SCs在大鼠脑内的存活、分化情况。方法黑质、前脑内侧束两点法注射6一羟多巴胺（6-OHDH）并行为学分析筛选PD模型大鼠。将PD模型大鼠随机分为移植组和对照组。BMSCs移植术后4周和8周,观察大鼠姿势不对称性,免疫组织化学及免疫荧光显色方法检测黑质和纹状体酪氨酸羟化酶（tyrosine hydroxylase,TH）的表达变化以及BMSCs在大鼠体内的存活、迁移及分化情况。结果BMSCs黑质内移植可使PD模型大鼠的转动频率由（10．62±2．97）r／min降至（4．65±1．08）r／min（P〈0．01）,显著增加毁损侧黑质TH阳性细胞数量和纹状体内TH阳性纤维密度。BMSCs在大鼠黑质内可以存活至少8周,部分细胞分化为神经干细胞、神经元和神经胶质细胞。结论黑质内移植BMSCs对PD模型大鼠有一定的治疗作用。     

贴壁法分离培养大鼠骨髓间充质干细胞的生物学特性

目的建立一种简便有效的体外分离纯化及培养扩增大鼠骨髓间充质干细胞(MSCs)的方法。研究MSCs的生物学特性,为血管组织工程提供理想的种子细胞。方法贴壁培养法分离纯化大鼠MSCs体外培养和连续传代,在倒置显微镜下连续观察细胞的形态变化;利用MTT法测定MSCs的生长曲线;行免疫组化方法鉴定MSCs膜抗原;分别加成骨、成脂肪诱导剂后MSCs体外培养1到3周,分别做碱性磷酸酶(ALP)、VonKossa染色及油红O染色,观察细胞形态变化、成骨及成脂肪分化结果。结果MSCs体外培养生长状况良好,呈均一的成纤维细胞样,表达波形蛋白(Vimentin)、α-平滑肌肌动蛋白(α-SMA),不表达层粘连蛋白(Laminin)、CD34、VIII因子相关抗原(VIII)。经体外诱导后具有多向分化潜能。结论贴壁培养法能有效分离纯化大鼠MSCs,用此方法培养的细胞生长稳定,增殖能力活跃,具有MSCs的一般生物学特性,为其成为血管组织工程理想的种子细胞提供了进一步的支持。     

人脐血间充质干细胞诱导分化为神经细胞的研究

目的探讨体外诱导人脐血间充质干细胞(MSCs)向神经细胞分化的条件,为治疗中枢神经系统损伤提供实用的干细胞来源。方法体外分离、纯化、扩增脐血MSCs,流式细胞仪检测细胞表面标志。采用脑源性神经营养因子BDNF 10ng/ml 维甲酸RA0.5μM 碱性成纤维生长因子bFGF 20ng/ml协同诱导脐血MSCs定向分化。免疫荧光染色检测诱导后细胞的星形胶质细胞特异标志GFAP及神经元特异标志MAP2的表达情况。建立大鼠脊髓横断损伤模型,将BrdU标记的诱导后的细胞移植入损伤的脊髓中,采用BBB运动功能评分标准在术后24h及1、2、3、4、5周各时间点对大鼠进行运动功能评分。用组织学和免疫组化方法检测移植到大鼠脊髓中的BrdU阳性细胞的存活、迁移、分化情况。结果脐血MSCs体外培养三代后,细胞表面CD11b、CD34、CD45和CD44表达阴性。诱导分化7d后,大部分细胞的形态类似神经元,免疫荧光染色检测MAP2阳性细胞占大多数,明显多于GFAP阳性细胞。5周后,细胞移植组大鼠的后肢运动功能恢复情况较对照组好。免疫组织化学结果显示植入的细胞可长时间在宿主脊髓中存活,并向损伤处两端迁移。结论人脐血MSCs于体外在特定的条件下可以诱导分化为神经元样细胞。移植脐血MSCs诱导后的神经细胞可在损伤的脊髓中存活、迁移,并能促进脊髓损伤后行为和功能恢复。     

不同分化状态下间充质干细胞向血管内皮生长因子的迁移

目的:探讨间充质干细胞(MSCs)对趋化因子VEGF的定向迁移能力与其分化状态之间的关系。方法:本实验运用采用Percoll分离法在体外培养并扩增大鼠骨髓来源MSCs,应用抗氧化剂诱导方案诱导MSCs向神经样细胞分化,运用Boyden chamber及Dunn chamber趋化性迁移装置研究了在趋化因子VEGF诱导下不同分化状态的间充质干细胞定向迁移,比较了各分化状态下细胞的迁移速度和迁移效率。结果:Boyden chamber实验结果显示下室加入不同浓度VEGF后,不同状态细胞向同一浓度VEGF迁移的数量不同,不同浓度VEGF诱导同一状态细胞的迁移数量也不同;Dunn chamber的实验结果显示在某一分化阶段(预诱导24小时)的MSCs具有更高的迁移效率。结论:MSCs的分化影响了其向VEGF的定向迁移,也就是说,不同分化状态的MSCs显示出不同的迁移行为。     

多巴胺合成相关酶基因联合治疗帕金森病大鼠模型的研究

目的 利用骨髓间充质干细胞（MSCs）作为运载细胞,携带DA合成代谢过程中3个重要相关酶的基因：酪氨酸羟化酶（TH）、芳香族氨基酸脱羧酶(AADC) 和三磷酸鸟苷酸环化水解酶-I (GCH-I)基因,治疗帕金森病(PD) 模型大鼠。方法 首先用重组病毒AAV-TH、AAV-AADC 和AAV-GCH-I的上清液对MSCs进行体外感染;将携带有TH、AADC和GCH-I基因的MSCs移植到PD模型大鼠纹状体内,检测纹状体及黑质内多巴胺及其代谢产物的变化,并观察其行为学的变化,以评估上述基因对PD大鼠的治疗作用。结果 重组假病毒颗粒感染MSCs后植入PD模型大鼠损伤侧纹状体内。通过逆转录聚合酶链反应 (RT-PCR) 和原位杂交的方法在移植后12w仍能检测到上述三种基因的表达。免疫荧光检测发现移植后12w MSCs在脑内存活良好;移植后4w、8w、12w行为学观察发现阿扑吗啡(APO)诱导旋转行为较对照组LacZ基因移植组有明显改善（p<0.01）;移植后12w时三重基因移植组较双重基因移植组有明显改善（p<0.01）。移植后12w用高效液相色谱（HPLC）电化学法测定损伤侧纹状体和黑质内DA及其代谢产物3,4-二羟苯丙酸（DOPAC）的含量,三重基因移植组较hTH+hGCH-I基因移植组有明显增高（p<0.01）;三重基因移植组较hTH+hAADC基因移植组有所增高,但两组之间没有显著性差异。结论 基因工程改造的MSCs 在移植到PD模型大鼠脑内后可以很好地表达目的基因并在对动物行为学及生化方面改善的长期观察中发现三重基因联合脑内移植可能是比双重基因联合移植更佳的帕金森病基因治疗途径。     

大鼠胚胎神经干细胞纹状体内移植后特性

观察大鼠胚胎神经干细胞移植入成年大鼠纹状体后的存活、迁移和分化状况。自14天胎鼠脑室下区分离获得神经干细胞,利用无血清培养基培养扩增并进行鉴定。经4～5代的扩增后,以BrdU标记的神经干细胞通过脑立体定位注射移植入成年大鼠纹状体内,然后分别于移植后2周、4周、6周和8周时做脑冰冻切片,通过免疫组织化学和免疫荧光方法检测移植细胞的数量、定位和分化情况。8周后移植细胞的检出率约16%;移植细胞向周围宿主组织有广泛的迁移表现,尤以沿着白质束向头尾方向的迁移最为显著,最远向后侧达到内囊;纹状体中移植细胞主要分化为神经元和星形胶质细胞。星形胶质细胞数量最多,主要位于移植区与宿主组织临界部位,而神经元处于移植区中央。培养的大鼠胚胎神经干细胞可以作为移植替代治疗神经退行性疾病研究的供体细胞源,而移植中的迁移现象值得注意。     

神经妥乐平体外诱导大鼠骨髓基质细胞分化为神经元样细胞

目的探索神经妥乐平(NT)体外诱导大鼠骨髓基质细胞(bone marrow stromal cells,rMSCs)分化为神经元样细胞的可行性,以期为临床应用MSCs治疗神经系统疾病奠定基础。方法取一月龄SD大鼠骨髓,分离出MSCs进行培养、扩增、纯化。用NT诱导MSCs分化为神经元样细胞。用神经元特异性烯醇化酶(NSE)、神经胶质纤维酸性蛋白(GFAP)免疫细胞化学染色鉴定阳性细胞。结果MSCs经诱导后胞体变圆,伸出细长突起,呈神经元样形态。免疫组化鉴定显示(31.50±7.32)%的细胞表达NSE阳性,(45.30±9.38)%的细胞表达GFAP阳性。结论MSCs在体外可被NT诱导分化为神经元样细胞。     

The Effect of Lentivirus-Mediated PSPN Genetic Engineering Bone Marrow Mesenchymal Stem Cells on Parkinson’s Disease Rat Model

Persephin (PSPN) is one of the neurotrophic factors of the glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) which have been found to promote the survival of specific populations of neurons. The aim of this study was to assess the potential therapeutic function of gene-modified mesenchymal stem cells (MSCs)-Lv-PSPN-MSCs in 6-OHDA-induced Parkinson’s disease (PD) rats models. Here, we worked on the isolation, purification, identification and amplification of MSCs in vitro. The expression analysis revealed that several of the neural marker proteins like nestin, GFAP and S100 were expressed by rat MSCs. MES23.5 cells co-cultured with Lv-PSPN-MSCs showed less 6-OHDA induced cell death than control cells in vitro. When Lv-PSPN-MSCs were injected into the striatum of PD rats, we observed the survival rate, migration, differentiation and the behavior change of PD rats. We found that Lv-PSPN-MSCs showed higher survival rate in rat brain compared with Lv-null-MSCs. Rotational behavior showed that rats receiving Lv-PSPN-MSCs showed the most significant improvement compared with those in other groups. HPLC results showed the content of DA in striatum of rats which received Lv-PSPN-MSCs was highest compared with those in other groups. In conclusion, our results suggest that transplantation of Lv-PSPN-MSCs can lead to remarkable therapeutic effects in PD rats.     

人羊膜上皮细胞移植及基因治疗帕金森病大鼠

观察人羊膜上皮细胞(human amniotic epithelial cell,HAEC及)人脑源性神经营养因子(brain-derived neurotrophic factor,BDNF基)因修饰的HAEC在帕金森病(Parkinson’sdisease,PD)模型大鼠脑内的长期存活和对旋转行为的治疗效果。用包装BDNFcDNA的慢病毒转染原代HAEC(HAEC/BDNF),HAEC/BDNF与HAEC分别植入6-羟基多巴胺损伤的PD模型大鼠纹状体内,观察动物的旋转行为,用免疫组织化学方法鉴定移植物在体内的存活。结果表明,治疗组PD大鼠的旋转行为改善明显达14周,HAEC/BDNF组能使恢复时间提前。免疫组织化学方法发现移植细胞在14周后仍有少量存活且部分表达BDNF、酪氨酸羟化酶,纹状体内星形胶质细胞增生。实验结果说明,HAEC和BDNF基因修饰的HAEC移植对PD模型大鼠的行为有一定改善,HAEC可以作为一种治疗PD的供体细胞。     

Multilineage potential of stable human mesenchymal stem cell line derived from fetal marrow

Human bone marrow contains two major cell types, hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs). MSCs possess self-renewal capacity and pluripotency defined by their ability to differentiate into osteoblasts, chondrocytes, adipocytes and muscle cells. MSCs are also known to differentiate into neurons and glial cells in vitro, and in vivo following transplantation into the brain of animal models of neurological disorders including ischemia and intracerebral hemorrhage (ICH) stroke. In order to obtain sufficient number and homogeneous population of human MSCs, we have clonally isolated permanent and stable human MSC lines by transfecting primary cell cultures of fetal human bone marrow MSCs with a retroviral vector encoding v-myc gene. One of the cell lines, HM3.B10 (B10), was found to differentiate into neural cell types including neural stem cells, neurons, astrocytes and oligodendrocytes in vitro as shown by expression of genetic markers for neural stem cells (nestin and Musashi1), neurons (neurofilament protein, synapsin and MAP2), astrocytes (glial fibrillary acidic protein, GFAP) and oligodendrocytes (myelin basic protein, MBP) as determined by RT-PCR assay. In addition, B10 cells were found to differentiate into neural cell types as shown by immunocytochical demonstration of nestin (for neural stem cells), neurofilament protein and beta-tubulin III (neurons) GFAP (astrocytes), and galactocerebroside (oligodendrocytes). Following brain transplantation in mouse ICH stroke model, B10 human MSCs integrate into host brain, survive, differentiate into neurons and astrocytes and induce behavioral improvement in the ICH animals. B10 human MSC cell line is not only a useful tool for the studies of organogenesis and specifically for the neurogenesis, but also provides a valuable source of cells for cell therapy studies in animal models of stroke and other neurological disorders.     

Heat shock protein 60 affects behavioral improvement in a rat model of Parkinson’s disease grafted with human umbilical cord mesenchymal stem cell-derived dopaminergic-like neurons

Parkinson’s disease (PD) is a neurodegenerative disorder that is caused by a loss of dopaminergic (DAergic) neurons in mesencephalic substantia nigra (SN). Human umbilical cord mesenchymal stem cells (hUC-MSCs) are capable of self-renewal and differentiation into multiple cell lineages, including DAergic neurons. Thus, hUC-MSCs could be a promising alternative to compensate for the loss of DAergic neurons in PD. In the current study, hUC-MSCs and hUC-MSCs-derived DAergic-like neurons were transplanted into the striatum and SN of a rat model of PD that is induced by 6-hydroxydopamine (6-OHDA). We evaluated their therapeutic effects on improving rotation behavior in the rat and on modulating the level of heat shock protein 60 (Hsp60) expression in the brain. After transplantation, an amelioration of rotation behavior was observed in rats that underwent cell grafting, and hUC-MSCs-derived DAergic-like neurons were superior to hUC-MSCs at inducing behavioral improvement. Western blot and immunohistochemistry analysis indicated significantly elevated levels of Hsp60 in cell-grafted rats compared to 6-OHDA-lesioned (PD) rats. These results demonstrate that hUC-MSCs-based cell transplantation is potential therapeutic treatment for PD, and hUC-MSCs-derived DAergic-like neurons appear to be favorable candidates for cell replacement therapy in PD. Finally, Hsp60 could be involved in a mechanism of behavioral recovery.     

Study of differentiated human umbilical cord–derived mesenchymal stem cells transplantation on rat model of advanced parkinsonism

The aim of this study was to explore the curative effect of differentiated human umbilical cord–derived mesenchymal stem cells (hUC‐MSCs) transplantation on rat of advanced Parkinson disease (PD) model. Human umbilical cord–derived mesenchymal stem cells were cultured and induced differentiation in vitro. The PD rats were established and allocated randomly into 2 groups: differentiated hUC‐MSCs groups and physiological saline groups (the control group). Rotation test and immunofluorescence double staining were done. The result showed that hUC‐MSCs could differentiate into mature dopamine neurons. Frequency of rotation was significantly less in differentiated hUC‐MSCs groups than in normal saline group. After we transplanted these cells into the unilateral lesioned substantia nigra induced by striatal injection of 6‐hydroxydopamine and performed in the medial forebrain bundle and ventral tegmental area, nigral tyrosine hydroxylase–positive cells were observed and survival of at least 2 months. In addition, transplantation of hUC‐MSCs could make an obviously therapeutic effect on PD rats.     

Isolation and characterization of mesenchymal stem cells derived from bone marrow of patients with Parkinson’s disease

Mesenchymal stem cells (MSCs) are capable of self-renewing and differentiating into multiple tissues; they are expected to become a source of cells for regenerative therapy. Compared to allogeneic MSCs, autologous MSCs from patients needing cell-based therapy may be an ideal alternative stem cell source. However, characterizations of MSCs from a disease state remains extremely limited. Therefore, we have isolated and characterized MSCs from Parkinson's disease (PD) patients and compared them with MSCs derived from normal adult bone marrow. Our results show that PD-derived MSCs are similar to normal MSCs in phenotype, morphology, and multidifferentiation capacity. Moreover, PD-derived MSCs are capable of differentiating into neurons in a specific medium with up to 30% having the characteristics of dopamine cells. At last, PD-derived MSCs could inhibit T-lymphocyte proliferation induced by mitogens. These findings indicate that MSCs derived from PD patients' bone marrow may be a promising cell type for cellular therapy and somatic gene therapy applications.     

Intrastriatal grafts of mesenchymal stem cells in adult intact rats can elevate tyrosine hydroxylase expression and dopamine levels

MSCs (mesenchymal stem cells) derived from the bone marrow have shown to be a promising source of stem cells in a therapeutic strategy of neurodegenerative disorder. Also, MSCs can enhance the TH (tyrosine hydroxylase) expression and DA (dopamine) content in catecholaminergic cells by in vitro co‐culture system. In the present study, we investigated the effect of intrastriatal grafts of MSCs on TH protein and gene levels and DA content in adult intact rats. When MSCs were transplanted into the striatum of normal rats, the grafted striatum not only had significantly higher TH protein and mRNA levels, but also significantly higher DA content than the untransplanted striatum. Meanwhile, the grafted MSCs differentiated into neurons, astrocytes and oligodendrocytes; however, TH‐positive cells could not be detected in our study. These experimental results offer further evidence that MSCs are a promising candidate for treating neurodegenerative diseases such as Parkinson's disease.